Neurofibromatose Typ 1
![](https://pacs.de/sites/default/files/pictures/thumbs/upload.wikimedia.org/4/8/1/5/2/Orbitadysplasie_bei_Neurofibromatose_Typ_1_-_MRT_-_FLAIR_axial_-_009_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/0/91c13037fcba1abe208f4b8843e0b4_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/6/6e4543dd89b0ba6cecf4a785d0db91_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/5/94a656335b9dd620e88e56947ce244_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/4/6301dfaf84bdf9538fe664242252c2_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/3/ba0db0861bce1cb0eda85d38d85372_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/1/ac742a7659c87f17daaed371491d0a_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/3/535498e0933d6bebe24ba6661b8307_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/9/89698bea17dedd7b5a04c6767199f9_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/8/8229b8d47c36fa3c5d49f4332a66fb_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/8/bed5edb8e773aec638806a08b0ed32_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/7/c87df72f964576ec3f1d995e092fe5_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/6/efe1d563226dc28662b379da4eee9c_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/5/9fb0d6d8b60bf4dd6f162f13c413fb_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/2/8/9/2/a43370e4fc8b5e17928b70fe0d0db1_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/2/0/0/1/5/renalarterystenosis01mdneurofibromatosisihypertensionmidaorticnarrowingbilateralrenalarterystenosisparvustardiswaveformsctus7yo_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/2/2/0/7/7/macrophthalmia01mdneurofibromatosisibilateralopticpathwaygliomathicktortuousopticnervest24yo_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/7/e60cafcfb36a02577c2ad87a59a682_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/2/425252caa6e2c64e51099ef94d8d7f_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/5/7/9/5/neurofibromatosisi01mdmoyamoyasyndromecafeaulaitspotshypoplasialefticastenosisocclusionleftcavernousandsupraclinoidicathinleftm1withoutcollateralsinbasalgangliaaneurysmslefta1anda2segmen_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/2/5262fbca7995952947512a2e0fc1fb_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/0/41abac8b546a25f87a969d7dde8747_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/7/9/09964fb4591c729d18e03c1d434bdfe279969c2c1f9a651b2d8dae92ff81cd91_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/1/8/0/9/13244_2015_401_Fig21_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/8/8/7/5/13244_2021_1095_Fig8_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/7/8/8/2/13244_2022_1166_Fig15_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/5/8/0/2/neurofibromatosisi02opticnervegliomabilateralseizuresmrt1post5yo_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/2/5/8/8/neurofibroma01cap31thoraxcxrpalatct_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/2/5/8/7/neurofibromatosis01jakneckchestbodywallcxrpalatcts12yo_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/4/5a3b9cd469e104f2f600bbea787131_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/2/3/8/5/neurofibromatosis03jakduralectasiamemincxrpamrt1s_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/upload.wikimedia.org/4/8/1/5/1/Optic_glioma_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/upload.wikimedia.org/4/8/1/5/5/Orbitadysplasie_bei_Neurofibromatose_Typ_1_-_MRT_-_T2_axial_-_009_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/9/9/4136f1828e10edb7002457e528bd5b_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/1/1/8/5/eea286a86f109e8440a8611d7a0d71aa8a8d563d91e36ce52c46beccf7bc668d_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/0/3/8/8/1/f84bca9b1bea91a543e57936401605_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/upload.wikimedia.org/4/8/1/5/3/Orbitadysplasie_bei_Neurofibromatose_Typ_1_-_MRT_-_T1_axial_-_009_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/3/0/3/5/9/neurofibromatosis03jakparaspinalneurofibromascoliosistspinepln_thumb.jpg)
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a multisystem neurocutaneous disorder, the most common phakomatosis, and a RASopathy. Additionally, it is also one of the most common inherited CNS disorders, autosomal dominant disorders, and inherited tumor syndromes.
Individual systemic manifestations are discussed individually:
- breast manifestations of NF1
- central nervous system manifestations of NF1
- cutaneous manifestations of NF1
- musculoskeletal manifestations of NF1
- pulmonary manifestations of NF1
- orbital manifestations of NF1
The remainder of this article pertains to a general discussion of neurofibromatosis type 1.
Epidemiology
Neurofibromatosis affects 1:2500-3000 individuals . In half of the cases, the disease is inherited as an autosomal dominant condition. In the other half, the disease is due to a de novo mutation . There is a variable expression but 100% penetrance by 5 years of age .
Clinical presentation
As is the case with many phakomatoses, NF1 results in a variety of abnormalities of variable severity. To make the clinical diagnosis two or more of the following are required :
- >6 cafe au lait spots evident during one year (prepubertal >0.5 cm, postpubertal >1.5 cm in size)
- two or more neurofibromas or one plexiform neurofibroma
- optic nerve glioma
- distinctive osseous lesion (such as sphenoid wing dysplasia or thinning of long bone cortex with or without pseudoarthrosis)
- two or more iris hamartomas (Lisch nodules)
- axillary or inguinal freckling
- a primary relative with NF1 with above criteria
A mnemonic to help remember these features is CAFE SPOT.
In addition, ~45% (range 30-60%) of patients have learning disabilities, and approximately 1% have hypertension due to renal artery stenosis.
It is important to consider that NF1 has a much earlier age of onset than schwannomatosis and NF2, with approximately 50% of patients meeting the diagnostic criteria for NF1 by the age of 1 year and approximately 97% meeting the criteria by the age of 8 years .
Neoplasms
It should come as no surprise that a disease due to inactivation of a tumor suppressor gene (see below) is also associated with an increased incidence of numerous tumors :
- pheochromocytoma
- malignant peripheral nerve sheath tumor (MPNST) ( ~10% of patients)
- Wilms tumor
- rhabdomyosarcoma
- renal angiomyolipoma
- glioma
- carcinoid tumor(s)
- leiomyoma(s)
- leiomyosarcoma
- ganglioglioma
- leukemia
Pathology
The NF1 gene locus is on chromosome 17q11.2 and the gene product is neurofibromin, which acts as a tumor suppressor of the Ras/MAPK pathway; inactivation of the gene thus predisposes to tumor development . For this reason, the disorder is classified as a RASopathy .
The disease primarily is a hamartomatous disorder that involves the ectoderm and mesoderm. Usually, three types of neurofibromas occur in this disorder and are distinguished on the basis of their gross and microscopic appearances.
- localized neurofibroma (cutaneous neurofibroma): the most common type, is a focal lesion that typically is located in the dermis and subcutis
- diffuse neurofibroma (subcutaneous neurofibroma): localized in the subcutis, usually in the head and neck region.
- plexiform neurofibroma: considered pathognomonic if present; they may be seen in virtually any location but usually occur in the neck, pelvis, and extremities
Radiographic features
Breast
Central nervous system
- FASI (focal areas of signal intensity): occur in deep white matter and basal ganglia or corpus callosum , areas of T2/FLAIR hyperintensity with no contrast enhancement
- optic nerve glioma or optic pathway glioma (may manifest as enlarged optic foramen)
- progressive sphenoid wing dysplasia
- lambdoid suture defects
- dural calcification at the vertex
- moya-moya phenomenon (rare)
- buphthalmos
Cutaneous
- cutaneous and subcutaneous neurofibromas: benign peripheral nerve sheath tumors
Skeletal
- kyphoscoliosis
- posterior vertebral scalloping
- hypoplastic posterior elements
- enlarged neural foramina
- ribbon rib deformity, rib notching, and dysplasia
- dural ectasia
- tibial pseudoarthrosis or, less commonly, ulnar pseudoarthrosis
- bony dysplasias: especially affecting tibia
- severe bowing, gracile bones
- multiple non-ossifying fibromas
- limb hemihypertrophy
Thoracic
- mediastinal masses
- neurofibroma
- lateral thoracic meningocele: typically on the convex side of scoliosis (through widened neural foramina)
- extra-adrenal pheochromocytoma
- lung parenchymal disease: ~20%
- diffuse interstitial fibrosis: lower zone
- bullae formation: upper zone
- secondary pulmonary arterial hypertension and cor pulmonale
Vascular
Treatment and prognosis
No single treatment exists, and a combination of supportive and surgical therapies are employed depending on the specific tumors and anomalies present.
Although prognosis is very variable, overall life expectancy is approximately half that of non-affected individuals. Tumors or cardiovascular complications are the most common causes of mortality .
History and etymology
The first name of this condition was Von Recklinghausen disease because, in 1882, von Recklinghausen described cases of neurofibromatosis and recognized it as a nosological entity .
See also
Siehe auch:
- Rippenusuren
- Arteriovenöse Malformation
- Pilozytisches Astrozytom
- Aortenisthmusstenose
- Angiomyolipom der Niere
- Aneurysma
- Rhabdomyosarkom
- Gangliogliom
- Nierenarterienstenose
- Karzinoid
- Leiomyosarkom
- Phäochromozytom
- Neurofibrom
- maligner peripherer Nervenscheidentumor (MPNST)
- diffuses intrinsisches Ponsgliom
- pulmonale Hypertonie
- Duraektasie
- Opticusgliom
- Nephroblastom
- Phakomatosen
- scalloping Wirbelkörper
- spinales Pilozytisches Astrozytom
- cafe-au-lait spots
- Moyamoya-Muster
- spinales Astrozytom
- pulmonale Bullae
- localized neurofibroma
- Orbitadysplasie
- neurofibromatosis of the breast
- plexiformes Neurofibrom
- different types of neurofibroma
und weiter:
- Fibröse Dysplasie
- Skoliose
- basal ganglia T1 hyperintensity
- multiple zystische Lungenherde
- Café-au-lait-Fleck
- Staphylom
- Makrozephalie
- macrodystrophia lipomatosa
- Moyamoya-Erkrankung
- Tibiaverbiegung bei Kindern
- intradural spinal mass lesions - an approach
- sphenoid wing dysplasia
- BIRADS II
- Verbiegung der langen Röhrenknochen
- Medulläres Schilddrüsenkarzinom
- congenital pseudoarthrosis
- stroke in children and young adults
- renovaskuläre arterielle Hypertonie
- dural ectasia of lumbo-sacral spine
- Neurofibromatose Typ 2
- Angiosarkom Leber
- vergrößerter Bulbus oculi
- Neurofibromatose
- multiple benign lucent bone lesions (mnemonic)
- bilateral megalencephaly
- Typen von Neurofibromen
- Erweiterung des interpedunculären Abstands
- localised neurofibroma
- fetal arachnoid cyst
- Neurofibromatose Typ 1 und Neurofibrosarkom
- radial pseudoarthrosis (congenital)
- Hemihyperplasie
- diffuse neurofibroma
- Triton-Tumor
- kongenitale Pseudarthrose der Fibula
- Neurocristopathien
- kongenitale Ulnapseudarthrose
- Nervenscheidentumor
- Neurofibromin
- bilateral optic nerve glioma, Neurofibromatosis type 1
- Makrodaktylie
- optic nerve glioma: neurofibromatosis type 1
- neurofibromatosis type 1 associated with a neurofibrosarcoma of the urinary bladder
- neurofibromatosis type 1: orbital manifestations
- Grisel-Syndrom
- Kongenitale Pseudarthrose der Tibia
- diffusion MRI of myelin vacuolization in NF1
- intracranial findings in neurofibromatosis type 1
- Megaloenzephalie
- mesenteric plexiform neurofibroma
- neurofibromatosis I affecting long bones
- Neurofibromatose Typ 1 und Pseudarthrose der Ulna
- neurofibroma of the ankle
- lokaler Gigantismus
- bare orbit sign
![Click für weniger anzeigen](/sites/all/modules/pacs/tools/imgs/collapse_up.png)
![](/sites/all/modules/pacs/tools/imgs/Iris_color_40.png)